Comparing the safety and effectiveness of plasma rich fibrin (PRF) to plasma rich platelet (PRP) in the treatment of periorbital rejuvenation and hyperpigmentation

Comparing the safety and effectiveness of plasma rich fibrin (PRF) to plasma rich platelet (PRP) in the treatment of periorbital rejuvenation and hyperpigmentation: a randomized double-blind clinical trial study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200127046282N51

Enrollment

Registered

2024-07-20

Start date

2024-07-20

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dark circles and wrinkles under the eyes. Chloasma of eyelid and periocular area

Interventions

Intervention 1: Intervention group: Patients will receive one cc of PRP and one cc of RPF in the left half of their face in two sessions, one month apart. Intervention 2: Intervention group: Patients

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 18-60 Darkness and wrinkles in the lower eyelid area Informed consent

Exclusion criteria

Exclusion criteria: Patients with malignancy Receiving chemotherapy in the past 5 years Patients with sepsis Smoking Pregnancy or breastfeeding Active wound or infection at the treatment site Receiving any topical or systemic medication in the past 3 months for under-eye darkness

Design outcomes

Primary

Measure	Time frame
Comparing the safety and effectiveness of plasma rich fibrin (PRF) to plasma rich platelet (PRP) in the treatment of periorbital rejuvenation and hyperpigmentation. Timepoint: In the study investigating the safety and efficacy of injecting fibrin-rich plasma (PRF) in treating aging and dark circles under the eyes compared to platelet-rich plasma (PRP), the time points for measuring dark circles and wrinkles are at 0, 3, 4, and 6 months after the start of the intervention. Method of measurement: In the study investigating the safety and efficacy of injecting fibrin-rich plasma (PRF) in treating aging and dark circles under the eyes compared to platelet-rich plasma (PRP), the measurement of outcome variables will be done through patient and physician satisfaction questionnaires, as well as through visioface biometric assessments.	—

Measure

Time frame

Comparing the safety and effectiveness of plasma rich fibrin (PRF) to plasma rich platelet (PRP) in the treatment of periorbital rejuvenation and hyperpigmentation. Timepoint: In the study investigating the safety and efficacy of injecting fibrin-rich plasma (PRF) in treating aging and dark circles under the eyes compared to platelet-rich plasma (PRP), the time points for measuring dark circles and wrinkles are at 0, 3, 4, and 6 months after the start of the intervention. Method of measurement: In the study investigating the safety and efficacy of injecting fibrin-rich plasma (PRF) in treating aging and dark circles under the eyes compared to platelet-rich plasma (PRP), the measurement of outcome variables will be done through patient and physician satisfaction questionnaires, as well as through visioface biometric assessments.

—

Secondary

Measure	Time frame
Satisfaction rate. Timepoint: Three months after the last meeting. Method of measurement: Comparing the severity of periorbital dark circles, before and after treatment (score from 0 - 10).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSona Zare

Skin and Stem cell Research Center of Tehran University of Medical Sciences

sonazarebio@gmail.com+98 21 2665 7438

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026